Sumitomo Pharma forecasts core sales of approximately 260 billion yen, core operating income of approximately 43 billion yen, and free cash flow of approximately 47 billion yen for FY2025, announcing a growth strategy targeting core product sales of 250 billion yen scale in the 2030s.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4506-20260302-03.pdf","jir_short_summary":"Sumitomo Pharma forecasts core sales of approximately 260 billion yen, core operating income of approximately 43 billion yen, and free cash flow of approximately 47 billion yen for FY2025, announcing a growth strategy targeting core product sales of 250 billion yen scale in the 2030s.","jir_summary":"### Advancement of Financial Goals and Growth Strategy\nSumitomo Pharma announced that it expects to achieve core 3 product sales of approximately 260 billion yen, core operating income of approximately 43 billion yen, and free cash flow of approximately 47 billion yen in FY2025, thereby advancing the financial targets set in Reboot 2027. The company will continue disciplined cost management of SG&A and R&D expenses to accelerate recovery-driven growth. A new mid-term management plan is planned, targeting sales of 250 billion yen for Orgovyx and 150 billion yen for Jemperli in the 2030s, while confirming direction for two oncology products.\n\n### Accelerating R&D and Business Growth\nThe company achieved approval application for the world\u2019s first iPS cell-derived pharmaceutical in Japan and has started physician-initiated clinical trials in North America. Clinical trials for two oncology products are also advancing. Sales of Orgovyx and Jemperli are growing substantially in North America, and the Asian business was restructured to focus on core operations, recording an equity method gain of 49 billion yen. The company is strengthening promotion based on scientific evidence, emphasizing the intrinsic value of its products.","jir_financial_highlights":"Core 3 Product Sales: Approx. 260 billion yen (FY2025 forecast) (Unknown)\nCore Operating Income: Approx. 43 billion yen (FY2025 forecast) (Unknown)\nFree Cash Flow: Approx. 47 billion yen (FY2025 forecast) (Unknown)\nEquity Method Gain on Sale of Affiliates: 49 billion yen (Asian business restructuring) (New)\nOrgovyx Sales: 1 billion USD (FY2025 forecast) (YoY +88%)\nJemperli Sales: 600 million USD (FY2025 forecast) (YoY +45%)","jir_category":"","jir_hashtags":"#SumitomoPharma, #BusinessStrategy, #MidTermManagementPlan, #JapaneseStocks","jir_key_figures":"Core 3 Product Sales: Approx. 260 billion yen (FY2025 forecast)\nCore Operating Income: Approx. 43 billion yen (FY2025 forecast)\nEquity Method Gain on Sale of Affiliates: 49 billion yen (Asian business restructuring)","jir_meta_title":"Sumitomo Pharma Announces FY2025 Core Product Sales Target of Approx. 260 Billion Yen and Growth Strategy for 2030s","jir_meta_description":"Sumitomo Pharma projects core 3 product sales of approximately 260 billion yen and core operating income of approximately 43 billion yen for FY2025 and unveils the growth acceleration strategy 'Boost 2028' targeting the 2030s.","jir_og_title":"Sumitomo Pharma Announces 'Boost 2028' Growth Strategy","jir_og_description":"Overview of Sumitomo Pharma\u2019s new strategy aiming to advance financial targets for FY2025 and significantly grow core product sales into the 2030s.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-32742","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n